Search Results

Today the Foster City-based company is the second-largest biotech employer in the Bay Area.

DNB Markets (“DNB”) and Back Bay Life Science Advisors (“Back Bay”), acting through the DNB//Back Bay Healthcare Partnership are pleased to announce the dates for our highly anticipated 9th annual Nordic-American Healthcare Conference (NAHC).

While San Diego remains a top biotech hub behind Boston and San Francisco, the city—which hosts this week’s BIO International Convention—has seen employment drop amid economic headwinds.

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and CEO, was named an Entrepreneur Of The Year® 2024 Bay Area Award finalist by EY.

City of Hope®, one of the largest cancer research and treatment organizations in the United States, announced that effective June 10, Angelique L. Richard, Ph.D., R.N., will be chief operating officer of City of Hope National Medical Center, City of Hope Los Angeles, City of Hope Orange County and City of Hope’s Southern California clinical network.

Vistagen today announced that company management will present and host one-on-one meetings during the 2024 RBC Capital Markets Global Healthcare Conference taking place May 14 and 15, 2024 in New York City.

GenomesDAO, a pioneering biotech company focused on the secure, private, and auditable monetization of genomic data, announced the successful completion of a new investment round led by Pantera Capital and Modular Capital.

InflaRx N.V. today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event to be held in New York City.

Bayer announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumors have activating HER2 mutations, and who have received a prior systemic therapy.